Pre-clinical studies demonstrate enhanced safety and efficacy of car-nk/t cells in haematological cancers, suggesting a flexible alternative to car-t cells.
Key Points
CAR-NK/T-cells offer a promising new approach for treating haematological cancers.
Pre-clinical studies highlight their ability to target key antigens like CD19 and BCMA effectively.
Compared to CAR-T-cells, CAR-NK/T-cells have faster immune responses and increased cytotoxicity.
Emerging innovations are overcoming challenges in NK/T-cell therapy, paving the way for further development.